Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab
Author:
Publisher
Elsevier BV
Subject
Neurology (clinical),Neurology,General Medicine
Reference3 articles.
1. The COVID-19 pandemic and the use of MS disease-modifying therapies;Giovannoni;Mult. Scler. Relat. Disord.,2020
2. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized opera I, opera II, and oratorio studies;Kappos;Mult. Scler. Relat. Disord.,2019
3. COVID-19 in a MS patient treated with Ocrelizumab: does immunosuppression have a protective role?;Novi;Mult. Scler. Relat. Disord.,2020
Cited by 33 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Outcome of COVID-19 Infection in Patients With Multiple Sclerosis Who Received Disease-Modifying Therapies: A Systematic Review and Meta-Analysis;Journal of Clinical Neurology;2023
2. Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical Viewpoint;Current Neuropharmacology;2022-01
3. Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: A systematic review and meta-analysis;Multiple Sclerosis and Related Disorders;2022-01
4. Predictors of Catching COVID-19 Infection during Pandemic Stage in Patients with Multiple Sclerosis (MS);International Journal of Preventive Medicine;2022
5. The Outcome of COVID-19 in Patients with a History of Taking Rituximab: A Narrative Review;IRAN J MED SCI;2021
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3